Investment Rating - The report maintains a BUY rating for Thermo Fisher with a new target price of US$670, up from the previous target price of US$654, indicating a potential upside of 15.8% from the current price of US$578.61 [2][8]. Core Insights - Thermo Fisher reported a strong performance in 4Q25, with revenue increasing by 7.2% year-over-year, marking the fastest quarterly growth in 2025. Adjusted EPS rose by 7.7%, surpassing Bloomberg consensus estimates by 2.2% and 1.9%, respectively [1][8]. - The company expects revenue growth of 3.9% to 5.9% and adjusted EPS growth of 5.9% to 8.4% for the full year 2026, reaffirming a long-term organic revenue growth target of 3%-6% [1][8]. Summary by Sections Financial Performance - For FY25, Thermo Fisher's revenue was US$44,556 million, with a year-over-year growth of 3.9%. The adjusted net profit was US$8,643 million, reflecting a growth of 3.1% [9][14]. - The company forecasts revenue of US$46,849 million for FY26, representing a growth of 5.1%, and adjusted net profit of US$9,130 million, which is a 5.6% increase [9][14]. Market Dynamics - The pharmaceutical and biotech sectors were the strongest client segments for Thermo Fisher in 2025, achieving mid-single-digit revenue growth for the year and high-single-digit growth in 4Q25. Management noted increased confidence among pharma companies in their relationships with governments [8]. - Biotech financing showed recovery in the second half of 2025, which is expected to drive revenue growth despite a typical lag of approximately six months between funding and R&D expenditure [8]. Strategic Acquisitions - In 2025, Thermo Fisher completed significant acquisitions, including Solventum's filtration and separation business for US$4.0 billion and Sanofi's sterile fill-finish facility for US$8.9 billion. These acquisitions are anticipated to enhance the company's global leadership in bioproduction and expand its capacity in the U.S. [8][9]. - Management expects adjusted EPS to grow by 7-9% in 2026 as a result of these strategic acquisitions [8]. Service Capabilities - Thermo Fisher's CDMO segment experienced strong growth in 2025, benefiting from limited sterile fill-finish capacity globally. The acquisition of Sanofi's facility is expected to secure growing orders for production in the U.S. [8]. - The integrated Accelerator business aims to improve project execution and reduce time-to-market for innovative drugs, thereby generating significant orders through differentiated service offerings [8].

Core Insights - Amphenol (APH) is expanding its portfolio and market presence through strategic acquisitions in communications, medical, and defense sectors, enhancing its high-technology interconnect solutions and supporting a diversified business model [1][2] - The company's acquisitions contributed 8% to its 2024 revenues, with approximately 15 acquisitions completed in the past nine quarters [1][2] - In Q1 2025, Amphenol reported sales of $4.8 billion, a 48% year-over-year increase, primarily driven by acquisitions [1][9] Strategic Acquisitions - Amphenol's acquisition strategy focuses on businesses that complement its core offerings and expand its presence in high-growth markets [2] - The acquisition of Conesys through the CIT acquisition in May 2024 strengthened Amphenol's capabilities in ruggedized connectors for aerospace, defense, and industrial applications [2] - The June 2022 acquisition of NPI Sensor Systems enhanced Amphenol's sensor-based technologies for automation and automotive segments [2] Recent Transactions - In Q1 2025, Amphenol closed two strategic transactions: the Andrew wireless infrastructure business and LifeSync [3] - The Andrew deal is expected to contribute approximately 9 cents to adjusted earnings, while the LifeSync acquisition expands Amphenol's interconnect product portfolio for medical applications [3] Competitive Landscape - Amphenol faces competition from companies like TE Connectivity (TEL) and Bel Fuse (BELFB) in key verticals such as telecom, defense, and industrial connectivity [4][6] - Bel Fuse is expanding in ruggedized connectors and defense-grade interconnects, which align with Amphenol's recent acquisitions [5] - TE Connectivity remains a strong competitor in high-speed interconnects and fiber-optic systems, challenging Amphenol across various markets [6] Financial Performance - Amphenol's shares have gained 42.2% year to date, outperforming the broader Zacks Computer & Technology sector's return of 6.1% and the Zacks Electronics - Connectors industry's increase of 40.3% [7] - The Zacks Consensus Estimate for Amphenol's Q2 2025 earnings is 66 cents per share, indicating a 53.49% year-over-year growth [13] - The consensus for APH's 2025 earnings is $2.68 per share, reflecting a 41.80% year-over-year increase [13] Valuation Metrics - Amphenol's stock is trading at a forward 12-month Price/Earnings ratio of 35.35X, compared to the sector's 27.23X [11] - The company currently holds a Zacks Rank 2 (Buy) [13]